Abstract: A sexual aid apparatus with a safety feature includes (a) a shaft element configured to emulate a human penis and to be placed against genitals or inside a human orifice, (b) an electric vibrating motor located within the shaft element, the electric vibrating motor configured for vibrating the shaft element so as to produce sensation in a user utilizing the shaft element against genitals or inside a human orifice, (c) a flexible cord coupled to a distal end of the shaft element, the cord configured for having a tensile strength of at least 20 pounds per square inch, (d) one or more spherical elements coupled to the cord and located between ends of the cord, the spherical elements configured for insertion into a human orifice and for producing sensation in the user; and (e) one or more crystal elements coupled to the cord and located between the ends of the cord, the crystal elements configured for insertion into a human orifice and for producing sensation in the user.

Abstract: A vibrating back massager with guide slot and vibrating heads is described. The guide slot is designed to restrict lateral movement of the massage device when the guide slot is engaged with a supporting member. The supporting member may be the edge of an open door, a corner, a vertical pole, or other generally available structure. The device includes a strap handle which may be draped over the user's shoulder and used to control the vertical position of the device. The described vibrating massage device allows a single user to create and maintain a significant amount of massage pressure without fatiguing his arms or relying on a second person. In a preferred embodiment, the controls for the vibrating massage device are incorporated into the strap handle so that the speed, intensity, and/or temperature may be controlled by the user without repositioning the device.

Abstract: A therapeutic flotation device and a therapeutic method of use thereof is disclosed. The device includes a plurality of buoyant float elements and a member (an elongated web strap) that couples each of the buoyant float elements such that the buoyant float elements are serially aligned along the member. A first end of the member is secured to a second end of the member. A mating mechanism, such as a buckle, secures the first end of the member to the second end of the member, or the two ends of the member may be permanently secured to each other using an adhesive or by being sewn together. Each of the buoyant float elements has a center aperture aligned along the center of a cross-section thereof. The member is preferably coupled to each of the buoyant float elements by being sequentially passed through the center apertures of each buoyant float element.

Abstract: The disclosure relates to a system for identifying medicines, comprising a first measurement device for identifying, from the top, at least one first medicine deposited in a compartment of a pill box and analysing at least one identifying characteristic of the first medicine; and a second measurement device for identifying, from the bottom, at least one second medicine deposited in the compartment of said pill box and analysing at least one identifying characteristic of the second medicine. The system comprises a device for comparing the characteristic of the first medicine and the characteristic of the second medicine, for determining at least one validated medicine and comparing the characteristic of the validated medicine with medicine signature characteristics. The system also comprises a validation device for obtaining an identified content for the compartment and comparing the identified content with a prescription. Methods for identifying and validating medicines are also disclosed.

Abstract: A syringe-to-syringe coupling for facilitating the transfer of fluids or medications from a first syringe to a second syringe. In example embodiments, the coupling includes a centrally-positioned hub extending from a first end to a second end, and a fluid delivery conduit provided within the hub and extending between the first and second ends. In example forms, each end of the hub includes a male tip.

Abstract: A resin composite containing azole-functionalized silica nanoparticles. The resin composite further includes a polymerizable monomer and a polymerization initiator system. A dental restoration fabricated by curing the resin composite is also specified.

Abstract: Provided is a curable composition comprising a polymerizable monomer (A); spherical particles (B) having an average primary-particle diameter in a range of 230 nm to 1,000 nm; and a polymerization initiator (C), in which 90% or more of individual particles constituting the spherical particles (B) lies in a range of ±5% based on the average primary-particle diameter, and the refractive index of the spherical particles (B) is larger than the refractive index of a polymer of the polymerizable monomer (A). When a 1 mm-thick cured product is formed from the curable composition and the Y value (Yb) of the colored light of the cured product on a black background and the Y value (Yw) of the colored light of the cured product on a white background are each measured using a color difference meter, the ratio therebetween, Yb/Yw, being within a range of 0.2 to 0.5.

Abstract: The invention relates to an oil-in-water emulsion for making up or caring for the lips. This emulsion contains a high proportion of glossy oils and is very fluid while remaining stable. This emulsion contains from 35% to 60% by weight of a mixture of oils, at least 25% by weight of water and from 0.01% to 20% of coloring material, everything being stabilized by the combination of a first polyethylene glycol ether of stearyl alcohol comprising from 2 to 5 oxyethylene units, a second polyethylene glycol ether of stearyl alcohol comprising from 15 to 25 oxyethylene units, and of a copolymer of acrylamido-2-methylpropane sulfonate and of hydroxyethyl acrylate.

Abstract: A hair coloring method that has a better property of keeping color quality, hardly damages hair, reduces skin damage and is free of paraphenylenediamine when performing hair dye comprises a step of applying a mixture of the following (A) and (B) in a predetermined ratio: (A) a hair coloring agent comprising at least a basic dye, an HC dye, a second amino acid, a first cationic surfactant, a thickener, an oil agent, a first pH adjuster and a wetting agent, wherein the hair coloring agent has a pH of 6.8 or more, and (B) a hair cosmetic comprising at least an alkaline agent, a first amino acid, a higher alcohol having 12 to 22 carbon atoms, a surfactant, and a thickener; a step of providing a predetermined time after applying; and a step of applying a cuticle care agent after the predetermined time.

Abstract: Provided are aqueous soluble tin phosphate complexes formed from a mixture comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., sodium tripolyphosphate (Na5P3O10), and oral care compositions comprising the complex and uses thereof.

Abstract: A method for forming a photosensitizer product that is resistant to absorption by living tissue that may include binding a photosensitizer compound with an oxide-containing particle to provide the photosensitizer derivative having a microscale size, and mixing the photosensitizer derivative into a lotion. The microscale size of the photosensitizer derivative obstructs absorption by cell tissue.

Abstract: A dermatological preparation comprises an optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents and the use of said preparation for skin care, hair care, or body care, or dental procedures, or for regenerative medicine such as promoting wound or bone healing. The preparation is formulated to target the hypoxic microenvironment niches of the skin tissue in combination with optimal concentration of nutrients, ions and minerals; to stimulate existing stem cells to trigger the capacity of stem cells to divide and renew and differentiate into specialized cells; and to stimulate molecular and physiological processes, e.g., autophagy, to replenish the substrate pool through the recycling of organelles and the recycling of old damaged proteins and countering free-radical damage to promote anti-aging.

Abstract: The invention relates to aqueous skin cleansing compositions. Specific amounts and chain length of acyl glycinate and acyl glutamate when used in specified ratios, have been found to unexpectedly enhance lather volume and texture, as well as provide superior mildness.

Abstract: One aspect of the present disclosure is a cosmetic composition containing a solubilized pigment and a method for preparing the same. More specifically, the cosmetic composition containing the solubilized pigment may be prepared through a process of dissolving a pigment in an aqueous phase by dispersing the pigment in the aqueous phase using a pigment dispersing thickener and stabilizing by further increasing the viscosity using a stabilizing thickener. Since the solubilized pigment exhibits dyeing properties similar to dyes, it can be widely applied to various cosmetic compositions.

Abstract: Process for thickening a composition, through the use of a direct emulsion in water, which is alkali-swellable, of a polymer of the ASE or HASE type, which is both rich in acrylic acid and which has a certain quantity of AMPS. The use of such emulsions simultaneously allows there to be no obligation to use surfactants and organic solvents other than water, and allows the thickening phenomenon to be activated for pHs of less than 7: this latter characteristic is particularly advantageous for formulations intended to be used in contact with skin.

Abstract: A mascara composition includes a film-forming polymer portion. The film-forming polymer portion is stabilized in a vehicle that includes water. The film-forming polymer portion includes a high molecular weight vinylpyrrolidone homopolymer and an acrylic polymer having a glass transition temperature of 65° C. or more. The mascara composition includes at least about 10 percent by weight of the vinylpyrrolidone homopolymer and is substantially free of wax. Methods of applying makeup to the eyelashes are also provided.

Abstract: The present invention relates to a cosmetic treatment and processes for treating keratinous materials, in particular for altering the color of hair as in hair coloration, hair color lightening or removal, and treatment of artificially colored hair, wherein the composition can include at least one antioxidant, applied separately or combined or combinable with one or more components of a color altering system in amounts sufficient to confer protection when the treatment composition is applied to keratinous material and thereby enhance and protect one or more sensorial features, and preserve the mechanical properties and native amino acid structure of the keratinous material.

Abstract: Methods in which an extract of Salvia miltiorrhiza roots is applied to the skin for a soothing cosmetic topical treatment. The invention also concerns a particular extract of Salvia miltiorrhiza roots, as well as compositions containing this extract and a cosmetic treatment method providing a soothing effect to the skin.

Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.

Abstract: A method (and the resulting product) of making a medical implant device for releasing self-contained drugs on a controlled basis wherein the method utilizes, at least in part, computer-controlled 3-D printing equipment to deposit via nozzles portions of one or more layers of the medical implant product. The implant has an outer impervious coating, an inner matrix core, an opening and an optional bonding layer.

Abstract: According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Abstract: The present invention is concerned with dispersible compositions comprising rilpivirine or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. Such compositions are useful in the treatment of HIV infection and their dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Abstract: The present invention relates generally to a methods of treating ear infections and clearing excess fluid from Eustachian tubes.

Abstract: The present invention relates to medical devices in the form of mucoadhesive films for the release of live lactic bacteria and bifidobacteria (probiotics) and/or for the release and maintenance of their pharmacologically useful enzyme activities.

Abstract: The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.

Abstract: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.

Abstract: Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.

Abstract: A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug.

Abstract: The present invention relates to topical formulations that include lipid microcapsules formed from tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component; and an aqueous component. The lipid microcapsules may be formed without the use of steroids, preservatives, initiators and/or oils. The topical formulations are capable of delivering transdermal active agent(s) such as vitamin D through the skin and into the bloodstream without the use of skin penetration enhancers. In certain embodiments, the topical formulations also able to deliver topical active agent(s) such as sun-protecting agents to the surface of the skin where they remain, while simultaneously delivering the transdermal active agent(s) through the skin and into the bloodstream.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.

Abstract: This invention provides an effective method and a composition for treating neurodegenerative diseases and conditions of the central and peripheral nervous system by stimulating neurogenesis by the use isoxylitones or an isomer, acid analog, a salt or a solvate, thereof.

Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.

Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.

Abstract: Disclosed herein are compositions and methods for increasing lifespan, for preventing or treating a disease including an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclosed herein are compositions and methods for improving effectiveness of a vaccine in a mammal. The compositions comprise, at least, a therapeutically effective amount of disulfiram and one or more additional ingredients.

Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.

Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Abstract: Therapeutic compounds useful for the treatment of pathogens including bacteria (gram positive and gram negative, mycobacteria), some fungi and viruses. The compounds described herein may include a mixture of therapeutically-effective amounts of a polar amino acid, a CI 1 fatty acid, and an anthraquinone. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from an infection.

Abstract: There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.

Abstract: The invention provides a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.

Abstract: In some aspects, provided herein are antimicrobial compositions comprising partially esterified polygalacturonic acid and certain fatty acids (e.g., caprylic acid). In some embodiments, the antimicrobial composition may be administered (e.g., topically or orally) to a subject, such as a human patient to treat an infection (e.g., an infection comprising a biofilm). In some aspects, improved catheters are provided.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aß expression; (ii) reduce Aß aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3ß protein; (vi) decrease the expression of GSK3ß protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.

Abstract: A medicament comprising a combination of a compound represented by formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.